Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates
暂无分享,去创建一个
A. Tefferi | M. Patnaik | T. Lasho | R. Ketterling | C. Hanson | C. Finke | K. Hoversten | N. Gangat | R. Vallapureddy
[1] A. Tefferi,et al. DNMT3A mutations are associated with inferior overall and leukemia‐free survival in chronic myelomonocytic leukemia , 2017, American journal of hematology.
[2] A. Tefferi,et al. CME Information , 2016, Stahl's Illustrated Sleep and Wake Disorders.
[3] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[4] A. Tefferi,et al. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia , 2015, Blood Cancer Journal.
[5] Anamarija M. Perry,et al. Extramedullary Hematopoiesis in a Sentinel Lymph Node as an Early Sign of Chronic Myelomonocytic Leukemia , 2015, Case reports in pathology.
[6] J. Messina,et al. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. , 2012, Leukemia research.
[7] S. Paydaş,et al. Granulocytic sarcoma: 32 cases and review of the literature , 2006, Leukemia & lymphoma.
[8] H. Kerl,et al. Specific cutaneous infiltrates in patients with myelogenous leukemia: a clinicopathologic study of 26 patients with assessment of diagnostic criteria. , 1999, Journal of the American Academy of Dermatology.
[9] C. Bradford,et al. Pericardial extramedullary haemopoiesis in chronic myelomonocytic leukaemia. , 1993, Journal of clinical pathology.